$38.38

-0.65 (-1.67%)

After Hours: $39.50 (+1.12, +2.92%)

Weekly Expected Move ±4.4%

$35 $37 $39 $41 $42

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 70 · $1.6B mcap · 40M float · 0.603% daily turnover · Short 57% of daily vol

Credit Risk of going bust: higher than 69% of companies Debt: 33.2% of company value Bonds: none of note held by US funds details ▾

Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.83 (down 95%), Phibro Animal Health Corporation would be worth roughly what it owes.
Total debt $788.8M against a stock market value of $1.58B.
Distance to default 3.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $378.9M (short-term plus half of long-term), stock volatility 55.3%; Altman Z 3.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$1.5B +17.1% ▲

5Y CAGR: +12.7%

Gross Profit

$512M +27.9% ▲

5Y CAGR: +13.5%

Operating Income

$198M +79.6% ▲

5Y CAGR: +21.5%

Net Income

$100M +106.6% ▲

5Y CAGR: +12.9%

EPS (Diluted)

$2.44 +105.0% ▲

5Y CAGR: +12.7%

EBITDA

$236M +61.0% ▲

5Y CAGR: +16.5%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$942M	$978M	$1.0B	$1.3B	$1.5B
YoY Growth	+13.1%	+3.8%	+4.1%	+27.4%	+17.1%
Cost of Revenue	$657M	$680M	$705M	$896M	$1.0B
Gross Profit	$285M	$298M	$313M	$400M	$512M
Gross Margin	30.3%	30.5%	30.8%	30.9%	33.7%
R&D Expenses	$0	$0	$0	$0	$0
SG&A Expenses	$206M	$226M	$260M	$289M	$313M
Operating Expenses	$206M	$226M	$260M	$289M	$313M
Operating Income	$79M	$72M	$53M	$110M	$198M
Operating Margin	8.4%	7.3%	5.2%	8.5%	13.1%
Interest Expense	$12M	$18M	$22M	$33M	$48M
Income Before Tax	$72M	$54M	$11M	$68M	$137M
Tax Expense	$23M	$21M	$8M	$20M	$38M
Net Income	$49M	$33M	$2M	$48M	$100M
Net Margin	5.2%	3.3%	0.2%	3.7%	6.6%
EPS (Diluted)	$1.21	$0.81	$0.06	$1.19	$2.44
EBITDA	$117M	$106M	$69M	$147M	$236M
Shares Outstanding	40M	41M	41M	41M	41M

Line Item	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2	FY2026 Q3	FY2026 Q4
Revenue	$260M	$309M	$348M	$379M	$364M	$374M	$384M	$397M
Cost of Revenue	$177M	$207M	$243M	$269M	$244M	$241M	$258M	$262M
Gross Profit	$83M	$102M	$105M	$110M	$120M	$133M	$125M	$134M
Gross Margin	32.1%	32.9%	30.1%	29.0%	32.9%	35.5%	32.6%	33.9%
R&D Expenses	$0	$0	$0	$0	$0	$0	$0	$0
SG&A Expenses	$66M	$76M	$71M	$76M	$71M	$78M	$77M	$86M
Operating Expenses	$66M	$76M	$71M	$76M	$71M	$78M	$77M	$86M
Operating Income	$18M	$26M	$34M	$34M	$48M	$54M	$48M	$48M
Operating Margin	6.8%	8.3%	9.6%	8.9%	13.2%	14.6%	12.5%	12.1%
Interest Expense	$8M	$9M	$13M	$8M	$13M	$13M	$11M	$10M
Income Before Tax	$10M	$5M	$30M	$24M	$36M	$36M	$32M	$32M
Tax Expense	$3M	$2M	$9M	$7M	$10M	$9M	$8M	$11M
Net Income	$7M	$3M	$21M	$17M	$27M	$27M	$24M	$22M
Net Margin	2.7%	1.0%	6.0%	4.5%	7.3%	7.3%	6.3%	5.5%
EPS (Diluted)	$0.17	$0.08	$0.51	$0.42	$0.65	$0.67	$0.59	$0.53
EBITDA	$27M	$26M	$51M	$45M	$63M	$62M	$56M	$56M
Shares Outstanding	41M	41M	41M	41M	41M	41M	41M	41M

PAHC NASDAQ